JP2002531138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002531138A5 JP2002531138A5 JP2000586939A JP2000586939A JP2002531138A5 JP 2002531138 A5 JP2002531138 A5 JP 2002531138A5 JP 2000586939 A JP2000586939 A JP 2000586939A JP 2000586939 A JP2000586939 A JP 2000586939A JP 2002531138 A5 JP2002531138 A5 JP 2002531138A5
- Authority
- JP
- Japan
- Prior art keywords
- dcf
- formation
- cyp3a4
- ketoconazole
- tao
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000015572 biosynthetic process Effects 0.000 description 5
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 4
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 description 4
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 description 4
- 229960004125 ketoconazole Drugs 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000004060 metabolic process Effects 0.000 description 4
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US09/205,762 | 1998-12-04 | ||
| US09/205,762 US6312917B1 (en) | 1998-12-04 | 1998-12-04 | Method of screening candidate compounds for susceptibility to oxidative metabolism |
| PCT/US1999/027130 WO2000034506A2 (en) | 1998-12-04 | 1999-11-15 | Method of screening candidate compounds for susceptibility to oxidative metabolism |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2002531138A JP2002531138A (ja) | 2002-09-24 |
| JP2002531138A5 true JP2002531138A5 (enExample) | 2006-09-14 |
Family
ID=22763550
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000586939A Pending JP2002531138A (ja) | 1998-12-04 | 1999-11-15 | 酸化代謝に対する感受性に関して候補化合物をスクリーニングする方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (2) | US6312917B1 (enExample) |
| EP (1) | EP1135521B1 (enExample) |
| JP (1) | JP2002531138A (enExample) |
| KR (1) | KR20010093140A (enExample) |
| AT (1) | ATE317914T1 (enExample) |
| AU (1) | AU774229B2 (enExample) |
| BR (1) | BR9916458A (enExample) |
| CA (1) | CA2352523A1 (enExample) |
| DE (1) | DE69929900T2 (enExample) |
| MX (1) | MXPA01005528A (enExample) |
| NZ (1) | NZ512217A (enExample) |
| WO (1) | WO2000034506A2 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6632630B2 (en) * | 2000-03-29 | 2003-10-14 | Aclara Biosciences, Inc. | Monooxygenase assays |
| WO2003102192A1 (en) * | 2002-05-30 | 2003-12-11 | Astex Technology Limited | Methods of purification of cytochrome p450 proteins and of their crystallizing |
| US20070179716A1 (en) * | 2001-04-02 | 2007-08-02 | Astex Therapeutics Limited | Crystal structure of cytochrome P450 3A4 and uses thereof |
| US20050032119A1 (en) * | 2001-04-02 | 2005-02-10 | Astex Technology Ltd. | Crystal structure of cytochrome P450 |
| US7148046B2 (en) * | 2001-04-02 | 2006-12-12 | Astex Therapeutics Limited | Crystal structure of cytochrome P450 |
| US20050159901A1 (en) * | 2001-04-02 | 2005-07-21 | Astex Technology Limited | Crystal structure of cytochrome P450 |
| JP2005512532A (ja) * | 2001-08-03 | 2005-05-12 | ディヴァーサ コーポレイション | Ｐ４５０酵素、それらをコードした核酸及びそれらの作製と使用 |
| US20040053383A1 (en) * | 2001-10-25 | 2004-03-18 | Astex Technology Ltd. | Crystals of cytochrome P450 2C9, structures thereof and their use |
| DE60214869T2 (de) * | 2001-10-25 | 2007-04-12 | Astex Technology Ltd., Cambridge | Cytochrome p450 2c9 kristalle, strukturen und dessen verwendung |
| US20040096874A1 (en) * | 2002-04-11 | 2004-05-20 | Third Wave Technologies, Inc. | Characterization of CYP 2D6 genotypes |
| GB0216203D0 (en) * | 2002-07-12 | 2002-08-21 | Imp Cancer Res Tech | Mondulation of cytochrome P450 reductase activity |
| EP1546162B1 (en) * | 2002-09-20 | 2011-06-22 | Promega Corporation | Luminescence-based methods and probes for measuring cytochrome p450 activity |
| DE03758362T1 (de) * | 2002-10-25 | 2005-08-25 | Astex Technology Ltd., Cambridge | Kristallstruktur des Cythochroms P450 3A4 und dessen Verwendung |
| WO2004078131A2 (en) * | 2003-03-01 | 2004-09-16 | Symyx Technologies, Inc. | Evaluating effects of exposure conditions on drug samples over time |
| WO2005098025A2 (en) * | 2004-04-05 | 2005-10-20 | The University Of North Carolina At Chapel Hill | High throughput reactive oxygen species-based cytochrome p450 inhibition assay |
| US20060046278A1 (en) * | 2004-08-26 | 2006-03-02 | Qualyst, Inc. | Methods and kits for determining metabolic stability of compounds |
| US20060223135A1 (en) * | 2005-04-05 | 2006-10-05 | The University Of North Carolina At Chapel Hill | High throughput reactive oxygen species-based cytochrome P450 inhibition assay |
| EP2778234B1 (en) | 2005-05-31 | 2017-09-27 | Promega Corporation | Luminogenic and fluorogenic compounds and methods to detect molecules or conditions |
| US20090318561A1 (en) * | 2008-06-23 | 2009-12-24 | Mutual Pharmaceutical Company, Inc. | Colchicine products, method of manufacture, and methods of use |
| WO2010021686A1 (en) | 2008-08-18 | 2010-02-25 | Promega Corporation | Luminogenic compounds and methods to detect cytochrome p450 3a enzymes |
| US9790537B2 (en) | 2014-01-29 | 2017-10-17 | Promega Corporation | Quinone-masked probes as labeling reagents for cell uptake measurements |
| WO2018118897A1 (en) * | 2016-12-19 | 2018-06-28 | Dice Molecules Sv, Llc | Methods of estimating metabolic stability of tagged combinatorial library compounds |
| WO2024223797A1 (en) | 2023-04-28 | 2024-10-31 | Institut National de la Santé et de la Recherche Médicale | Use of cyp3a4 inhibitors for the treatment of hepatitis d virus (hdv) infections |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4341868A (en) * | 1978-08-18 | 1982-07-27 | Kyowa Hakko Kogyo Co., Ltd. | Method and test composition for the determination of the substrate for xanthine oxidase |
| DE2965849D1 (en) | 1978-08-18 | 1983-08-18 | Kyowa Hakko Kogyo Kk | Method and test composition for the determination of a substrate for xanthine-oxidase, including a novel xanthine-oxidase and method for the preparation thereof |
| JP2515551B2 (ja) * | 1987-06-08 | 1996-07-10 | 和光純薬工業株式会社 | 新規な過酸化水素の定量方法 |
| US5413915A (en) | 1988-07-12 | 1995-05-09 | Resource Technologies Group, Inc. | Method and sensor for detecting toxic chemical exposure effects and metabolic activation of carcinogenic chemical agents |
| AU1970897A (en) | 1996-04-15 | 1997-11-07 | Fox Chase Cancer Center | Assays for detection of purine metabolites |
| GB9821932D0 (en) | 1998-10-09 | 1998-12-02 | Univ Leicester | Cytochrome P450 electrochemical system |
-
1998
- 1998-12-04 US US09/205,762 patent/US6312917B1/en not_active Expired - Fee Related
-
1999
- 1999-11-15 KR KR1020017006953A patent/KR20010093140A/ko not_active Ceased
- 1999-11-15 MX MXPA01005528A patent/MXPA01005528A/es not_active IP Right Cessation
- 1999-11-15 JP JP2000586939A patent/JP2002531138A/ja active Pending
- 1999-11-15 CA CA002352523A patent/CA2352523A1/en not_active Abandoned
- 1999-11-15 AT AT99957569T patent/ATE317914T1/de not_active IP Right Cessation
- 1999-11-15 AU AU15250/00A patent/AU774229B2/en not_active Ceased
- 1999-11-15 WO PCT/US1999/027130 patent/WO2000034506A2/en not_active Ceased
- 1999-11-15 BR BR9916458-2A patent/BR9916458A/pt not_active Application Discontinuation
- 1999-11-15 NZ NZ512217A patent/NZ512217A/en not_active IP Right Cessation
- 1999-11-15 EP EP99957569A patent/EP1135521B1/en not_active Expired - Lifetime
- 1999-11-15 DE DE69929900T patent/DE69929900T2/de not_active Expired - Fee Related
-
2001
- 2001-11-05 US US09/993,842 patent/US20020058295A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04002137A (es) | Inhibidores de glicogen sintasa quinasa-3 (gsk-3) para el tratamiento del glaucoma. | |
| AU2002302587A1 (en) | Acne treatment with lipooxigenase inhibitors | |
| ATE368726T1 (de) | Im wesentlichen sedimentfrei dispergierbares wasch- oder reinigungsmittel | |
| JP2001019484A5 (enExample) | ||
| ATE305307T1 (de) | Reboxetin zur behandlung von migränekopfschmerzen | |
| MY117521A (en) | Polishing composition | |
| WO2000045799A3 (de) | Verwendung von substituierten isoxazolcarbonsäuren und derivaten und neue stoffe | |
| CY1108563T1 (el) | Μεθοδοι και υλικα για τη θεραπεια της ανεπαρκειας (ελλειψης) τεστοστερονης στους ανδρες | |
| DE60017878D1 (de) | Kombinationspräparate zur behandlung von erkrankungen, die mit angiogenese verbunden sind | |
| WO2003006670A3 (en) | 2-[5-(5-carbamimidoyl-1h-heteroaryl)-6-hydroxybiphenyl-3-yl]-succinic acid derivatives as factor viia inhibitors | |
| DE50009744D1 (de) | Verfahren zur herstellung eines oxids | |
| MY134255A (en) | Process for producing part made of magnesium and/or magnesium alloy | |
| ATE331824T1 (de) | Mittel zur korrosionsverhütung | |
| WO2002034815A8 (en) | Compositions and methods for treating surfaces | |
| AU5170400A (en) | Topical application of muscarinic and opioid agents for treatment of tinnitus | |
| ATE553415T1 (de) | Lichtempfindliche polyimid-precursor- zusammensetzungen | |
| DE60326007D1 (de) | Inhibierung der kristallisation von kolophonium | |
| DE50205466D1 (de) | Substituierte 2,5-diamidoindole als ece-inhibitoren zur behandlung von kardiovaskulären erkrankungen | |
| WO2002051848A3 (de) | Sulfamidothienopyrimidine zur verwendung als phosphodiesterase v-hemmer | |
| AU2003272007A1 (en) | Use of n-5-4-(4-methylpiperaziomethyl)-benzoylamido!-2-methylphenyl!-4-(3-pyridyl)2-pyridine-amine for the treatment of pulmonary hypertension | |
| EE200100510A (et) | Vesikeskkonnas kasutatav keraamiline toode ning selle määrdumisvastaseks töötlemise meetod | |
| AU7846301A (en) | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and topoisomerase i and ii inhibitors | |
| AU2002231777A1 (en) | Use of mglur5 antagonists for the treatment of pruritic conditions | |
| WO2002017858A3 (en) | Role of fosb in bone formation | |
| FI953002A0 (fi) | Menetelmä kroonisen eturauhastulehduksen hoitamiseksi 17beta-N-monosubstituoiduilla karbamoyyli-4-atsa-5alfa-androst-1-en-3-oneilla |